Jett Foundation

❤️💻 TOMORROW: Join Jett Foundation's Community Webinar: Transition of Care to learn more about preparing for this important milestone, building your care team, and accessing resources.

📅 Register today and join us tomorrow for this important discussion: www.jettfoundation.org/event/community-webinar-transition-of-care

On June 30, 2026, Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action data of February 28, 2027.

Find full updates via their release and Community Letter: https://www.jettfoundation.org/duchenne-news/sarepta-shares-community-letter-and-release-sarepta-announces-fda-for-acceptance-of-sndas-for-amondys-45-and-vyondys-53/